Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06195241 · ClinicalTrials.gov registry record · Phase 4
Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
A Phase 4 study of Benign Essential Blepharospasm and Hemifacial Spasm, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06195241 is a Phase 4 study of Benign Essential Blepharospasm and Hemifacial Spasm that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06195241, a Phase 4 study of Benign Essential Blepharospasm and Hemifacial Spasm, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer: 1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify? 2. What percentage of patients achieve a clinical response? Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.
Conditions Studied
Interventions
- DRUG DaxibotulinumtoxinA
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2027-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06195241
The ClinicalTrials.gov registry entry for NCT06195241 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Benign Essential Blepharospasm appearing as the primary indexed condition, and to 1 intervention - of which DaxibotulinumtoxinA is the first listed.
NCT06195241 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06195241 about?
NCT06195241 is a clinical study titled "Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm". The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer: 1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score...
What is the current status of trial NCT06195241?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2025-02-11. Estimated completion is 2027-03.
What conditions does trial NCT06195241 study?
This clinical trial studies the following conditions: Benign Essential Blepharospasm, Hemifacial Spasm.
What interventions are being tested in trial NCT06195241?
The interventions under investigation include: DaxibotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT06195241?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06195241 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Essential Blepharospasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.